Key Insights

Highlights

Success Rate

77% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

15.0%

9 terminated out of 60 trials

Success Rate

76.9%

-9.6% vs benchmark

Late-Stage Pipeline

20%

12 trials in Phase 3/4

Results Transparency

33%

10 of 30 completed with results

Key Signals

10 with results77% success

Data Visualizations

Phase Distribution

44Total
Not Applicable (25)
P 1 (1)
P 2 (6)
P 3 (6)
P 4 (6)

Trial Status

Completed30
Unknown9
Terminated9
Recruiting6
Not Yet Recruiting3
Withdrawn1

Trial Success Rate

76.9%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (60)

Showing 20 of 20 trials
NCT06848010Not ApplicableNot Yet RecruitingPrimary

TRacheal Cuff PRessure Evaluation Study

NCT06039995Not ApplicableCompletedPrimary

The Efficacy of Adjuvant Oral Care in Prevention of Ventilator Associated Pneumonia.

NCT07350122Not ApplicableNot Yet Recruiting

BIS in ICU Interventional Study

NCT05405491Not ApplicableActive Not RecruitingPrimary

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation

NCT03149640Phase 3CompletedPrimary

Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia

NCT03711331Not ApplicableCompletedPrimary

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia

NCT05843786Phase 3RecruitingPrimary

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

NCT07052604RecruitingPrimary

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT06467864RecruitingPrimary

Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response

NCT04215692Not ApplicableSuspended

Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients

NCT00986102Phase 4Completed

PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region

NCT05117125RecruitingPrimary

Biomarkers for Ventilator-associated Pneumonia

NCT06607055RecruitingPrimary

Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia

NCT03527992Not ApplicableRecruiting

Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia

NCT04566172Not ApplicableWithdrawn

Preoperative Optimization to Improve Functional Status

NCT06370598Phase 1Not Yet RecruitingPrimary

Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia

NCT05214716Not ApplicableTerminatedPrimary

FilmArray Pneumonia Panel for Antimicrobial Treatment of HAP/VAP in Intensive Care Units

NCT03816956Phase 3Completed

Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

NCT02689531CompletedPrimary

CTTI Risk Factors for HABP/VABP Study

NCT02326207Not ApplicableTerminatedPrimary

Weekly Versus no Routine Ventilator Circuit Changes in NICU

Scroll to load more

Research Network

Activity Timeline